BDBM176228 US10047103, 261::US9688695, 261

SMILES COc1cc(OCc2csc(Nc3ccc4[nH]ccc4c3)n2)c2cc(oc2c1)-c1cn2nc(C)ccc2n1

InChI Key InChIKey=CSISELVUJFQQMR-UHFFFAOYSA-N

Data  1 IC50  3 EC50

Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 176228   

TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Co.

US Patent
LigandPNGBDBM176228(US10047103, 261 | US9688695, 261)
Show SMILES COc1cc(OCc2csc(Nc3ccc4[nH]ccc4c3)n2)c2cc(oc2c1)-c1cn2nc(C)ccc2n1
Show InChI InChI=1S/C28H22N6O3S/c1-16-3-6-27-32-23(13-34(27)33-16)26-12-21-24(10-20(35-2)11-25(21)37-26)36-14-19-15-38-28(31-19)30-18-4-5-22-17(9-18)7-8-29-22/h3-13,15,29H,14H2,1-2H3,(H,30,31)
Affinity DataEC50:  39nMT: 2°CAssay Description:Briefly, HEK293 EBNA PAR4 clone 20664.1J cells were plated 24 hrs. prior to experiment in 384 well, Poly-D-Lysine coated, black, clear bottom plates ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb Co.

US Patent
LigandPNGBDBM176228(US10047103, 261 | US9688695, 261)
Show SMILES COc1cc(OCc2csc(Nc3ccc4[nH]ccc4c3)n2)c2cc(oc2c1)-c1cn2nc(C)ccc2n1
Show InChI InChI=1S/C28H22N6O3S/c1-16-3-6-27-32-23(13-34(27)33-16)26-12-21-24(10-20(35-2)11-25(21)37-26)36-14-19-15-38-28(31-19)30-18-4-5-22-17(9-18)7-8-29-22/h3-13,15,29H,14H2,1-2H3,(H,30,31)
Affinity DataIC50: 3.00E+3nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Co.

US Patent
LigandPNGBDBM176228(US10047103, 261 | US9688695, 261)
Show SMILES COc1cc(OCc2csc(Nc3ccc4[nH]ccc4c3)n2)c2cc(oc2c1)-c1cn2nc(C)ccc2n1
Show InChI InChI=1S/C28H22N6O3S/c1-16-3-6-27-32-23(13-34(27)33-16)26-12-21-24(10-20(35-2)11-25(21)37-26)36-14-19-15-38-28(31-19)30-18-4-5-22-17(9-18)7-8-29-22/h3-13,15,29H,14H2,1-2H3,(H,30,31)
Affinity DataEC50:  39nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
TargetProteinase-activated receptor 4(Homo sapiens (Human))
Bristol-Myers Squibb Co.

US Patent
LigandPNGBDBM176228(US10047103, 261 | US9688695, 261)
Show SMILES COc1cc(OCc2csc(Nc3ccc4[nH]ccc4c3)n2)c2cc(oc2c1)-c1cn2nc(C)ccc2n1
Show InChI InChI=1S/C28H22N6O3S/c1-16-3-6-27-32-23(13-34(27)33-16)26-12-21-24(10-20(35-2)11-25(21)37-26)36-14-19-15-38-28(31-19)30-18-4-5-22-17(9-18)7-8-29-22/h3-13,15,29H,14H2,1-2H3,(H,30,31)
Affinity DataEC50: >3.00E+3nMT: 2°CAssay Description:Briefly, PRP or washed platelet suspension (100 μl) was pre-incubated for 5 minutes at room temperature with varying concentrations of compounds...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid